Every letter we have printed

One practical note from the other side of the counter. When a customer asks us for the gradient we send it. When a customer asks a reseller, the reseller does not have it, because they were sent a PDF with a number on it. The gap you are describing is often two links down the chain rather than at the laboratory.

Sub-two-micron columns changed everything about what is practical for peptide separations, but I would push back on the statement that particle size gains are costless. The pressure limit of most commercial instruments is three hundred bar, and trying to force 1.7-micron particles at eight millilitres per minute on a 4.6-millimetre column will send you there quickly. Peak capacity is not free.

On column temperature: the article treats it as one variable among twelve, but for peptides it is closer to a second gradient. Raising the compartment from thirty to sixty degrees sharpens peaks and can reverse an elution order. A certificate that states a temperature is telling you more than a certificate that states a column.

The recombinant reagent alternatives have matured and are accepted in several pharmacopoeias now. That development removes the last practical objection anybody raised about supply of the traditional reagent.

Endotoxin is not a sterility question and the two are treated as one throughout this market. A preparation can be sterile and carry endotoxin, because the material is a fragment of a cell wall and survives the process that killed the organism.

Media fill frequency and the number of units filled are the two figures that characterise an aseptic operation, and they are the two that never leave the building. A company confident in its suite could publish them tomorrow with no commercial exposure whatever.

A quibble about depyrogenation. You imply an operation describing autoclaving alone has skipped a step, but depyrogenation of glass is only necessary if the incoming glass carries endotoxin. Vials supplied ready-to-use from a component manufacturer arrive already depyrogenated and certified as such.

You describe the appearance line as decorative. It is not. Colour, cake structure and collapse are the only observations recorded before anything is dissolved, and a collapsed cake with an intact vacuum is a real finding about the lyophilisation cycle. It is the cheapest line on the page and one of the few that is not a number.

Units are quietly inconsistent across this trade. Water content by weight and water content by the Karl Fischer determination are usually the same thing and occasionally are not, and the abbreviation on the page does not distinguish them.

A note on the chain between synthesis and certificate. The document that matters is the one that names who took the sample and when. A report on a sample the seller chose, packed and posted describes that sample honestly and describes the lot only by assumption, and the assumption is the part nobody writes down.

You describe reused chromatogram images as a tell. I work in a contract laboratory and I would note that some data systems export a representative overlay rather than the individual injection, so identical-looking traces can occur legitimately across a batch series. It is still worth asking about; it is not the smoking gun your article implies.

Extrapolating a composition ratio to a different rate of loss is the error I see most often. The relationship is not linear in any dataset I have read, and applying a percentage from a slow-loss cohort to a fast-loss one has no support at all.

A ratio derived from a substudy of eighty people is being applied to a population of millions in general discussion, and the arithmetic is presented with a confidence the original authors were careful to avoid. The paper is fine; the citation chain is where the damage happens.

Grams per kilogram of what is the question nobody asks. Total mass, lean mass and a reference mass give substantially different targets for the same person, and the literature uses all three without always saying which.

Reduced activity is a plausible consequence of reduced intake and it is measured in hardly any of these studies. If total activity falls during the trial, part of the composition result is downstream of that rather than of anything else.

The archive is the asset. Being able to follow one question across three years of issues is a different experience from reading any single piece, and very few publications make it possible.

Composition endpoints are collected in a minority of these studies and reported in fewer. A weight curve after withdrawal without a composition measurement leaves the most interesting question unanswered.

Where a study offered continued support to both arms, the comparison is between two managed groups rather than between management and nothing. That is a better design and a narrower question, and coverage rarely notes which was run.

What a gradual reduction may do is provide a period in which habits are established while some effect remains, which is a behavioural rationale rather than a pharmacological one. Stating which kind of rationale is on offer would clarify a confused discussion.

The follow-up periods in these studies are shorter than the period readers care about. Reporting that plainly, rather than extending the observed trajectory in the reader’s imagination, is the honest treatment and your piece does it.

I came to this department sceptical of the whole enterprise and I have stayed for three years. The scepticism has survived and it now has better material to work with.

Dose-response data in this class flattens well before the top of the studied range on most endpoints, which is the actual argument against escalation. It is a stronger argument than the one usually made and it comes from published curves.

Exposure varies several-fold between individuals at the same nominal dose, which means a population ceiling and a personal one are different numbers. The pharmacokinetic variability is published and rarely quoted.

You describe the plateau as an energy-balance event and dismiss receptor desensitisation. Is there not a third possibility — that adherence quietly falls off at around a year and the plateau is partly a behavioural artefact of the trial rather than a physiological one?

Your list of what you asked suppliers for is the right list and I would add one item: the environmental monitoring trend rather than a single result. A trend shows whether a suite is under control; one plate shows what happened on one day.

The most useful outcome of this series for me has been the vocabulary. I can now ask a supplier a question that is specific enough to have an answer, which was not true a year ago, and specific questions get answered far more often than general ones.

The statistics section is the part of this I will be sending to people. I had assumed a passed sterility test meant something about the batch. It had not occurred to me that a batch with one contaminated vial in a hundred passes four times out of five.

The reason nobody discusses this is partly that discussing it invites a use-case that the research-use framing exists to avoid. The silence is structural rather than evasive.

Attrition produces apparent plateaus mechanically. If people whose trajectory flattens leave the study at a different rate from those whose does not, the remaining group mean moves for reasons that have nothing to do with anybody’s response.

A plateau in a group mean and a plateau in an individual are different phenomena, and the first can occur while nobody in the study is experiencing the second. Averaging across people with different trajectories produces curves that describe no participant.

The comparison that would put these figures in proportion is composition change under any other route to the same mass loss. That comparison exists in the older literature, it is unflattering to the argument on both sides, and it is almost never cited.

An honest presentation would give the ratio with its confidence interval and the sample size in the same sentence. Three numbers instead of one, and the impression created would be entirely different.

Research-use language belongs on the certificate rather than only on the invoice. A document that describes a material without stating what it is not approved for is a document that will be read as broader than it is.

The signature block is not decoration. A named analyst with a role, over a determination date, is a person who can be asked a question. A scanned signature with no name under it is an image.

On the recycling of a genuine document across later lots: this is the failure mode I meet most often in the wider market, and it is the hardest to characterise, because nothing on the page is false. The determination happened. It simply happened to a different batch than the one in the parcel.

I would like the trade to adopt a convention on significant figures. A specification of not less than 98 per cent and a result of 98.04 per cent are a pass by two hundredths of a point, which is well inside the repeatability of the method. The certificate should carry the method repeatability alongside the limit, or the pass means nothing.

Laboratories are accountable to whoever pays them, which is ordinary commercial life. What is unusual here is that the person relying on the report is almost never that person, and there is no mechanism by which they become one.

The anaesthetic guidance in this area has moved considerably in a short time and the versions circulating are not all current. A publication reporting on it should date the guidance it describes, because a reader acting on a superseded version is acting on something that has been withdrawn.

The periprocedural guidance in this area moved quickly and the underlying evidence did not, which produced a period in which different professional bodies said different things about the same question. That history is worth documenting because it explains the current disagreement.

Meal composition interacts with the mechanism in ways the literature has measured and popular coverage never mentions. Fat content in particular changes emptying substantially at baseline, before anything else is introduced.